Global $13.3Bn Cephalosporin Market by Generation, Route of Administration, Application, and Region – Forecast to 2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering.

The global cephalosporin market size was worth US$ 11.4 Billion in 2018. Looking forward, the market is projected to reach a value of US$ 13.3 Billion by 2024, registering a CAGR of around 3% during 2019-2024.

At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide.

Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focuses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market.

Key Questions Answered

• How has the global cephalosporin market performed so far and how will it perform in the coming years?
• What are the key regional markets in the global cephalosporin industry?
• What is the breakup of the market based on the generation?
• What is the breakup of the market based on the route of administration?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the global cephalosporin industry?
• What are the key driving factors and challenges in the global cephalosporin industry?
• What is the structure of the global cephalosporin industry and who are the key players?
• What is the degree of competition in the global cephalosporin industry?
• What are the profit margins in the global cephalosporin industry?

Topics Covered

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Cephalosporin Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Breakup by Generation

5.4 Market Breakup by Route of Administration

5.5 Market Breakup by Application

5.6 Market Breakup by Region

5.7 Market Forecast

6 Market Breakup by Generation

6.1 First Generation

6.2 Second Generation

6.3 Third Generation

6.4 Fourth Generation

6.5 Fifth Generation

7 Market Breakup by Route of Administration

7.1 Injection

7.2 Oral

8 Market Breakup by Application

8.1 Respiratory Tract

8.2 Skin Infection

8.3 Ear Infection

8.4 Urinary Tract Infection

8.5 Sexually Transmitted Infection

8.6 Others

9 Market Breakup by Region

9.1 Asia-Pacific

9.2 Europe

9.3 North America

9.4 Middle East & Africa

9.5 Latin America

10 SWOT Analysis

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 Price Analysis

13.1 Price Indicators

13.2 Price Structure

13.3 Margin Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Allergan PLC

14.3.2 Bristol-Myers Squibb Company

14.3.3 F. Hoffmann-La Roche Ltd.

14.3.4 GlaxoSmithKline PLC

14.3.5 Lupin Limited (Lupin Pharmaceuticals Inc.)

14.3.6 Merck & Co. Inc.

14.3.7 Novartis International AG (Sandoz)

14.3.8 Pfizer Inc.

14.3.9 Teva Pharmaceutical Industries Ltd.

14.3.10 Abbott

14.3.11 Ranbaxy

14.3.12 Merck

For more information about this report visit https://www.researchandmarkets.com/r/rnyz2

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Antibiotics